ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,712,158 | +24.8% | 431,546 | +41.3% | 0.05% | +31.6% |
| Q2 2023 | $9,386,951 | -52.3% | 305,366 | -44.1% | 0.04% | -56.3% |
| Q1 2023 | $19,698,826 | +87.2% | 546,734 | +105.3% | 0.09% | +70.6% |
| Q4 2022 | $10,524,136 | +55.8% | 266,299 | +58.3% | 0.05% | +45.7% |
| Q3 2022 | $6,757,000 | -36.5% | 168,173 | -33.6% | 0.04% | -32.7% |
| Q2 2022 | $10,647,000 | -7.2% | 253,266 | -14.0% | 0.05% | +15.6% |
| Q1 2022 | $11,470,000 | +57.9% | 294,399 | +61.5% | 0.04% | +66.7% |
| Q4 2021 | $7,266,000 | -41.0% | 182,331 | -46.5% | 0.03% | -51.8% |
| Q3 2021 | $12,323,000 | -69.0% | 340,979 | -64.8% | 0.06% | -68.0% |
| Q2 2021 | $39,761,000 | +2.4% | 970,006 | +9.0% | 0.18% | -0.6% |
| Q1 2021 | $38,811,000 | +196.9% | 889,751 | +240.7% | 0.18% | +214.3% |
| Q4 2020 | $13,070,000 | – | 261,145 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |